|
Session 158
Poster Abstracts
Pharmacokinetics in Children
Monday, 1-2:30 pm
Poster Hall |
879
 |
Pharmacokinetics and Dose Selection of Etravirine in HIV-infected Children between 6 and 17 Years, Inclusive
Christoph Königs*1, C Feiterna-Sperling2, S Esposito3, C Giaquinto4, T Kakuda5, R Sinha6, R MacK5, K Janssen6, and R Hoetelmans6
1J W Goethe Univ, Frankfurt, Germany; 2Klinikum Humboldt University, Berlin, Germany; 3Università di Milano, Milan, Italy; 4Università di Padova, Padova, Italy; 5Tibotec, Inc, Yardley, PA, US; and 6Tibotec BVBA, Mechelen, Belgium |
880
|
Lopinavir Population Pharmacokinetic Model and Dose Simulation Predicts Rapid Increase in Exposure for HIV-infected Infants Initiating Therapy at <6 Months of Age
Mina Nikanjam*1, E Capparelli1, B Robbins2, J Pinto3, C Alvero4, R Yogev5, P Palumbo6, M Hughes4, J Rodman7, E Chadwick5, and IMPAACT P1030 Team
1Univ of California, San Diego, US; 2Univ of Nebraska Med Ctr, Omaha, US; 3Federal Univ of Minas Gerais, Belo Horizonte, Brazil; 4Harvard Sch of Publ Hlth, Boston, MA, US; 5Northwestern Univ, Chicago, IL, US; 6Dartmouth Univ, Hanover, NH, US; and 7St Jude Children`s Res Hosp, Memphis, TN, US |
881
|
Pharmacokinetics of Nevirapine in 3- to 6-kg, HIV-infected Infants Taking Pediatric Fixed-dose Combination Tablets
Veronica Mulenga*1, Q Fillekes2, D Kabamba1, C Kankasa1, M Thomason3, A Ferrier3, S Walker3, D Gibb3, C Chintu1, and D Burger2
1Univ Teaching Hosp, Lusaka, Zambia; 2Radboud Univ Nijmegen Med Ctr, Nijmegen, The Netherlands; and 3Med Res Council, London, UK |
882
|
A Novel Chewable Pediatric Fixed-dose Combination of Stavudine, Lamivudine, Nevirapine: Pharmacokinetics and Safety in HIV-infected Thai Children
Nirun Vanprapar*1, T Cressey2,3, E Capparelli4, K Chokephaibulkit1, V Sirisanthana5, S Hongsiriwan6, K McIntosh2, W Prasitsuebsai1, P Muresan2, and R Yogev7
1Siriraj Hosp, Bangkok, Thailand; 2Harvard Sch of Publ Hlth, Boston, MA, US; 3Program for HIV Prevention and Treatment, Chiang Mai Univ, Thailand; 4Univ of California, San Diego, US; 5Res Inst for Hlth Sci, Chiang Mai Univ, Thailand; 6Chonburi Regional Hosp, Thailand; and 7Children`s Memorial Hosp, Chicago, IL, US |
| 883 |
Are Recommended Dosages of Efavirenz Optimal in Young Children? ANRS 12103
Déborah Hirt*1,2, S Urien2, M Olivier3, H Peyrière3, B Nacro4, S Diagbouga5, E Zouré4, F Rouet5, P Van De Perre3, and J-M Tréluyer1,2
1Univ. Paris - Descartes, Paris, France; 2Hosp. Tarnier, Paris, France; 3Hosp. Lapeyronie, Montpellier, France; 4Hosp. Sourô Sanou, Bobo Dioulasso, Burkina Faso; and 5Ctr. Muraz, Bobo Dioulasso, Burkina Faso |
884
|
Age-related Pharmacokinetics of Efavirenz Solution
Edmund Capparelli*1, M Rochon-Duck1, B Robbins2, M Rathore3, P Britto4, C Hu4, A Weinberg5, R Browning6, R Hazra7, R McKinney Jr8, and IMPAACT P1021 Study Team
1Univ of California, San Diego, US; 2Univ of Nebraska Med Ctr, Omaha, US; 3Univ of Florida, Jacksonville, US; 4Harvard Sch of Publ Hlth, Boston, MA, US; 5Univ of Colorado, Denver, US; 6NIAID, NIH, Bethesda, MD, US; 7Natl Inst of Child Hlth and Human Devt, NIH, Bethesda, MD, US; and 8Duke Univ, Durham, NC, US |
| 885 |
Efavirenz Plasma Concentrations and the Association with CYP2B6-516 T Polymorphism in HIV-infected Thai Children
Thanyawee Puthanakit*1, P Tanpaiboon2, L Aurpibul3, T Cressey3, and V Sirisanthana2
1Res Inst for Hlth Sci, Chiang Mai Univ, Thailand; 2Chiang Mai Univ, Thailand; and 3Prgm for HIV Prevention and Treatment, Chiang Mai Univ, Thailand |
| 886 |
Didanosine Population Pharmacokinetics in West African HIV-infected Children Administered Once-daily Tablets in Relation to Efficacy after 1 Year of Treatment: ANRS 12103
Déborah Hirt*1,2, C Bardin3, S Diagbouga4, B Nacro5, H Hien4, F Rouet4, A Ouiminga4, P Van De Perre6, J-M Tréluyer2,7, and P Msellati8
1Univ. Paris - Descartes, Paris, France; 2Hosp. Tarnier, Paris, France; 3Hôtel-Dieu, Paris, France; 4Ctr. Muraz, Bobo Dioulasso, Burkina Faso; 5Hosp. Sourô Sanou, Bobo Dioulasso, Burkina Faso; 6Univ. Montpellier 1, Montpellier, France; 7Hosp Cochin-Saint-Vincent-de-Paul, Paris, France; and 8Ctr. de Recherche Cultures Santé Sociétés/IFEHA, Univ. Paul Cézanne, Aix en Provence, France |
887
|
Pharmacokinetic Study of Once- vs Twice-daily Abacavir and Lamivudine as Part of Combination ART in Children with HIV-1 Infection aged 3 to 36 months: Pediatric European Network for Treatment of AIDS 15 and ANRS 133
Evelyne Jacqz-Aigrain*1, L Farrelly2, A Compagnucci3, L Harrison2, W Zhao1, D Hamadache4, S Welch5, U Wintergerst6, G Firtion7, D Burger8,9, and Penta 15 Trial Steering Committee
1Hopital Robert Debré, Paris, France; 2Med Res Council, London, UK; 3INSERM SC10, Paris, France; 4Imperial Coll Hlthcare NHS Trust, London, UK; 5Birmingham Heartlands Hosp, UK; 6Universitats-kinderliniken, Munich, Germany; 7Hosp Port-Royal, Paris, France; 8University Medical Centre Nijmengen, The Netherlands; and 9Nijmegen University Center for Infectiuos Diseases (NUCI), Nijmegen, The Nederlands |
|
